Date | Compound | Laboratory | Indication | Type of Information |
---|---|---|---|---|
2015-02-11 | bivalent anti-human myostatin adnectin-IgG1 | BMS (USA - NY) | Duchenne muscular dystrophy |
Granting of a patent |
2015-02-19 | bovine lactoferrin | Metrodora Therapeutics (USA - WA) | prevention of late-onset sepsis in very low birth weight infants |
Granting of the orphan status in the US |
2015-02-23 | bovine lactoferrin | Metrodora Therapeutics (USA - WA) | prevention of necrotizing enterocolitis in very low birth weight infants (birth weight less than or equal to 1500 grams) |
Granting of the orphan status in the US |
2015-01-05 | celiprolol | Acer Therapeutics (USA - MA) | Ehlers-Danlos syndrome |
Granting of the orphan status in the US |
2014-12-22 | chromium picolinate and chromium histidinate | JDS Therapeutics (USA - NY) | pediatic polycystic ovary syndrome (0 through 16 years of age) |
Granting of the orphan status in the US |
2014-10-27 | clenbuterol | Duke University Medical Center (USA - NC) | adjunctive therapy with enzyme replacement therapy in the treatment of Pompe disease |
Granting of the orphan status in the US |
2014-12-17 | cytochrome P450 isoform 2B1 gene transfected human embryonic kidney 293 cells encapsulated in polymeric cellulose sulphate | Nuvilex, now Pharmacyte Biotech (USA - MD) | pancreatic cancer in combination with ifosfamide |
Granting of the orphan status in the US |
2018-09-20 | adeno-associated viral vector type 2 expressing human recombinant retinal pigment epithelial 65KDa protein gene | Spark Therapeutics (USA - PA) Novartis (Switzerland) |
|
Positive opinion for the granting of a Market Authorisation in the EU |
2015-04-09 | DBV Technologies (France) | peanut allergy in children |
Granting of the Breakthrough Therapy status | |
2018-09-18 | cabozantinib | Exelixis (USA - CA) Ipsen (France) |
|
Granting of a Market Authorisation in Canada |
2015-03-18 | clonidine Lauriad® | Onxeo (France) | oral mucositis in patients treated for a head and neck cancer | Granting of a patent |
2015-04-10 | Nestlé Health Science (Switzerland) | cow milk allergy |
Product launch | |
2015-08-17 | brentuximab vedotin | Seattle Genetics (USA - MA) | Hodgkin lymphoma (HL) patients at high risk of relapse | Granting of a Market Authorisation in the US |
2015-03-05 | dendritic cell vaccines | Medigene (Germany) | Granting of a patent | |
2015-11-25 | cobimetinib in combination with Zelboraf® (vemurafenib) | Roche (Switzerland) Exelixis (USA - CA) | stage IIb, IIc, III, and IV melanoma with BRAFV600E mutation | Granting of a Market Authorisation in the EU |
2015-04-15 | diphenylcyclopropenone gel | RXi Pharmaceuticals (USA - MA) | malignant melanoma stage IIB to IV |
Granting of the orphan status in the US |
2015-04-02 | C24H28N8O7S2 | Curis (USA - MA) | diffuse large B-cell lymphoma |
Granting of the orphan status in the US |
2015-03-19 | (monomethoxypolyethylene glycol) recombinant adenosine deaminase | Sigma-Tau Pharmaceuticals (USA - MD) | adenosine deaminase deficiency in patients with severe combined immunodeficiency |
Granting of the orphan status in the US |
2015-04-24 | 1-(4-(N-glycylamido)phenyl)-3-trifluoromethyl-5-(phenanthren-2-yl)-pyrazole-hydrochloride | Arno Therapeutics (USA - NJ) | tularaemia |
Granting of the orphan status in the EU |
2015-04-24 | 1-(4-(N-glycylamido)phenyl)-3-trifluoromethyl-5-(phenanthren-2-yl)-pyrazole-hydrochloride | Arno Therapeutics (USA - NJ) | cryptococcosis |
Granting of the orphan status in the EU |
© 2024 Biopharmanalyses - Powered by Samacom+